1. Home
  2. ARTL vs VBIO Comparison

ARTL vs VBIO Comparison

Compare ARTL & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$2.35

Market Cap

1.4M

Sector

Health Care

ML Signal

N/A

Logo Valion Bio Inc. Common Stock

VBIO

Valion Bio Inc. Common Stock

HOLD

Current Price

$0.62

Market Cap

1.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARTL
VBIO
Founded
2011
2016
Country
United States
United States
Employees
N/A
52
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4M
1.4M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
ARTL
VBIO
Price
$2.35
$0.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.3K
★ 518.5K
Earning Date
11-11-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $780,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.52
$0.12
52 Week High
$179.19
$812.50

Technical Indicators

Market Signals
Indicator
ARTL
VBIO
Relative Strength Index (RSI) 32.73 21.69
Support Level $0.52 $0.12
Resistance Level $6.81 $4.39
Average True Range (ATR) 0.17 0.17
MACD 0.03 1.48
Stochastic Oscillator 18.33 1.19

Price Performance

Historical Comparison
ARTL
VBIO

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About VBIO Valion Bio Inc. Common Stock

Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.

Share on Social Networks: